Beyond Air, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon, everyone. Thank you for joining us here today. I'm here with Bob from Beyond Air. Thank you for taking the time. Why don't we just go ahead and start at a high level for investors who are newer to your story? Can you just explain what inhaled nitric oxide is, where it's used today, the problem that Beyond Air is trying to solve with LungFit?
All right, sure. Inhaled nitric oxide, it's a drug.
Okay Within the market that it operates in our company, where we operate, it's in a hospital setting.
Okay? And the product is actually delivering inhaled nitric oxide, a drug, out of ambient air through our device. So a medical device creating a drug out of thin air, literally out of thin air. I'm sorry, what was that other question?
Where it's used today Oh, where it's used.
Yeah. Yeah. In the hospital system and predominantly in the neonatal ICU.
Okay. Yeah. Okay. If you could just pinpoint the problem that you guys are trying to solve with your product.
Yeah. Listen, the product itself, not our company, but the product itself has been out for decades.
Okay. Inhaled nitric oxide in the setting that we're in.
So we're not delivering anything that they're not used to seeing the delivery of inhaled nitric oxide. The problem we're solving is a logistical issue.
Okay That respiratory therapists and neonatologists and nurses and value add teams, procurement, they've all complained about the logistics that are involved with the delivery of inhaled nitric oxide.
And the issue, well, the additional issue to that was that they thought that they would be able to get a product that would immediately kind of turn the corner, and it was decades until we came along. And now that we're here, we're able to deliver that cleaner version for them where there's not a logistical issue.
Okay, so there was a big gap in the market.
Huge gap. Okay. Yeah, so my understanding is that the inhaled nitric oxide market, it historically relied on these large cylinders of gas, whereas LungFit generates nitric oxide from the ambient air, which we just covered.
Yep. Can you just walk us through why that is important and what changes operationally when a hospital moves from cylinder-based to LungFit?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring